慢性精神分裂症认知障碍的辅助美金刚治疗：一项安慰剂对照的初步研究。
Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study.
机构信息
Department of Psychiatry, Haeundae Paik Hospital, College of Medicine and Paik Institute for Clinical Research, Inje University, Busan, Korea.
出版信息
Psychiatry Investig. 2012 Jun;9(2):166-73. doi: 10.4306/pi.2012.9.2.166. Epub 2012 May 22.
Abstract
OBJECTIVE
To investigate the effects of memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, on cognitive impairments in patients with chronic schizophrenia.
METHODS
A 12-week, placebo-controlled trial was conducted to determine the effectiveness of memantine as an adjunctive treatment with conventional antipsychotic medications in 26 patients with chronic schizophrenia. The subjects were evaluated with the Korean version of the Mini-Mental State Examination (K-MMSE), the Positive and Negative Syndrome Scale (PANSS), the Hamilton Rating Scale for Depression (HAM-D), and a standard neuropsychological screening test.
RESULTS
Memantine treatment was not associated with significantly improved cognitive test scores compared with the placebo control treatment. An improvement in the scores on the PANSS negative subscale was noted with memantine, but it was not significant.
CONCLUSION
Adjunctive memantine treatment did not improve cognitive functioning or affect psychopathology in patients with chronic schizophrenia in the present study. Memantine, however, was tolerated well and did not exacerbate positive symptoms in patients with chronic schizophrenia.
摘要
目的
研究 N-甲基-D-天冬氨酸（NMDA）受体拮抗剂美金刚对慢性精神分裂症患者认知障碍的影响。
方法
进行了一项为期 12 周的安慰剂对照试验，以确定美金刚作为常规抗精神病药物辅助治疗对 26 例慢性精神分裂症患者的有效性。采用韩国版简易精神状态检查（K-MMSE）、阳性和阴性综合征量表（PANSS）、汉密尔顿抑郁量表（HAM-D）和标准神经心理学筛查测试对受试者进行评估。
结果
与安慰剂对照组相比，美金刚治疗与认知测试评分的显著改善无关。美金刚治疗后 PANSS 阴性量表评分有所改善，但无统计学意义。
结论
在本研究中，美金刚辅助治疗并未改善慢性精神分裂症患者的认知功能或影响精神病理学。然而，美金刚耐受性良好，不会加重慢性精神分裂症患者的阳性症状。
相似文献
1
Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study.慢性精神分裂症认知障碍的辅助美金刚治疗：一项安慰剂对照的初步研究。
Psychiatry Investig. 2012 Jun;9(2):166-73. doi: 10.4306/pi.2012.9.2.166. Epub 2012 May 22.
2
Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study.精神分裂症的辅助美金刚治疗：一项双盲、随机、安慰剂对照研究。
J Clin Psychopharmacol. 2019 Nov/Dec;39(6):634-638. doi: 10.1097/JCP.0000000000001115.
3
Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.N-乙酰半胱氨酸（NAC）辅助治疗慢性精神分裂症症状的疗效：一项双盲、随机临床试验。
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:289-296. doi: 10.1016/j.pnpbp.2017.11.001. Epub 2017 Nov 7.
4
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.难治性精神分裂症阴性和阳性症状的改善：一项双盲、随机、安慰剂对照试验，以美金刚作为氯氮平的附加治疗。
J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry.
5
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.一项关于美金刚作为精神分裂症患者辅助治疗的随机、安慰剂对照研究。
Neuropsychopharmacology. 2009 Apr;34(5):1322-9. doi: 10.1038/npp.2008.200. Epub 2008 Nov 12.
6
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.精神分裂症的辅助性美金刚治疗：一项随机、双盲、安慰剂对照试验的荟萃分析。
Psychol Med. 2018 Jan;48(1):72-81. doi: 10.1017/S0033291717001271. Epub 2017 May 22.
7
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.氯氮平治疗难治性精神分裂症时加用美金刚：一项开放标签的1年延长期研究。
Psychol Med. 2017 Jan;47(2):363-375. doi: 10.1017/S0033291716002476. Epub 2016 Oct 25.
8
Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial.盐酸美金刚联合利培酮治疗精神分裂症的疗效：一项随机、双盲、安慰剂对照临床试验。
Psychiatry Res. 2017 Jan;247:291-295. doi: 10.1016/j.psychres.2016.09.028. Epub 2016 Sep 21.
9
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.一项为期12周的双盲、安慰剂对照试验，评估加兰他敏辅助传统抗精神病药物治疗慢性精神分裂症认知障碍的效果。
Int Clin Psychopharmacol. 2007 Mar;22(2):63-8. doi: 10.1097/YIC.0b013e3280117feb.
10
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.美金刚联用利培酮治疗稳定期精神分裂症阴性症状的随机、双盲、安慰剂对照研究。
J Clin Psychopharmacol. 2013 Jun;33(3):336-42. doi: 10.1097/JCP.0b013e31828b50a7.
引用本文的文献
1
Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.美金刚治疗精神分裂症原发性阴性症状：随机对照试验的荟萃分析
Clin Drug Investig. 2025 Sep;45(9):627-642. doi: 10.1007/s40261-025-01465-4. Epub 2025 Aug 1.
2
Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis.45种用于精神分裂症的增效药物的综合评价：一项网状Meta分析。
EClinicalMedicine. 2024 Feb 7;69:102473. doi: 10.1016/j.eclinm.2024.102473. eCollection 2024 Mar.
3
The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial.美金刚与叶酸对精神分裂症患者认知障碍的影响：一项随机临床试验。
Iran J Psychiatry. 2023 Jul;18(3):258-265. doi: 10.18502/ijps.v18i3.13002.
4
Unveiling the Enigma: Exploring Risk Factors and Mechanisms for Psychotic Symptoms in Alzheimer's Disease through Electronic Medical Records with Deep Learning Models.揭开谜团：通过电子病历和深度学习模型探索阿尔茨海默病中精神病症状的风险因素和机制
Pharmaceuticals (Basel). 2023 Jun 21;16(7):911. doi: 10.3390/ph16070911.
5
Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review.增强疗法作为精神分裂症共存躯体问题的治疗方法——一项系统综述
J Clin Med. 2023 Jun 12;12(12):4012. doi: 10.3390/jcm12124012.
6
Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease.转化生长因子及其受体水平低效是导致老年成为阿尔茨海默病风险因素的原因。
Alzheimers Dement (N Y). 2019 Dec 9;5:899-905. doi: 10.1016/j.trci.2019.11.007. eCollection 2019.
7
Clozapine augmentation strategies.氯氮平增效策略。
Ment Health Clin. 2019 Nov 27;9(6):336-348. doi: 10.9740/mhc.2019.11.336. eCollection 2019 Nov.
8
Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.抗精神病药物-加兰他敏-美金刚联合用药在治疗精神分裂症阳性、认知及阴性症状中的潜在作用
Mol Neuropsychiatry. 2018 Dec;4(3):134-148. doi: 10.1159/000494495. Epub 2018 Nov 19.
9
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis.不同类型认知增强剂对精神分裂症患者的疗效：一项荟萃分析。
NPJ Schizophr. 2018 Oct 25;4(1):22. doi: 10.1038/s41537-018-0064-6.
10
Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.用于精神分裂症、双相情感障碍、阿尔茨海默病和帕金森病患者认知增强的药物。
Front Psychiatry. 2018 Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection 2018.
本文引用的文献
1
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.难治性精神分裂症阴性和阳性症状的改善：一项双盲、随机、安慰剂对照试验，以美金刚作为氯氮平的附加治疗。
J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry.
2
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.一项关于美金刚作为精神分裂症患者辅助治疗的随机、安慰剂对照研究。
Neuropsychopharmacology. 2009 Apr;34(5):1322-9. doi: 10.1038/npp.2008.200. Epub 2008 Nov 12.
3
Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.对有残留症状的精神分裂症住院患者在抗精神病治疗中加用美金刚：一项初步研究。
Eur Neuropsychopharmacol. 2008 Feb;18(2):117-21. doi: 10.1016/j.euroneuro.2007.07.008. Epub 2007 Aug 28.
4
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.美金刚治疗轻至中度阿尔茨海默病患者：一项随机、双盲、安慰剂对照的6个月研究结果
J Alzheimers Dis. 2007 Jul;11(4):471-9. doi: 10.3233/jad-2007-11409.
5
Molecular targets for treating cognitive dysfunction in schizophrenia.治疗精神分裂症认知功能障碍的分子靶点。
Schizophr Bull. 2007 Sep;33(5):1100-19. doi: 10.1093/schbul/sbm074. Epub 2007 Jul 7.
6
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.一项为期12周的双盲、安慰剂对照试验，评估加兰他敏辅助传统抗精神病药物治疗慢性精神分裂症认知障碍的效果。
Int Clin Psychopharmacol. 2007 Mar;22(2):63-8. doi: 10.1097/YIC.0b013e3280117feb.
7
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.美金刚治疗轻至中度阿尔茨海默病：一项为期24周的随机对照试验。
Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15. doi: 10.1097/01.JGP.0000224350.82719.83.
8
Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.美金刚对阿尔茨海默病的神经保护及症状改善作用——关于作用机制的统一谷氨酸能假说
Neurotox Res. 2000;2(2-3):85-97. doi: 10.1007/BF03033787.
9
[Memantine as an adjunctive therapy for schizophrenia negative symptoms].[美金刚作为精神分裂症阴性症状的辅助治疗]
Braz J Psychiatry. 2005 Sep;27(3):257-8. doi: 10.1590/s1516-44462005000300023. Epub 2005 Oct 4.
10
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients.金刚烷胺或安慰剂对药物治疗的精神分裂症患者视觉运动和认知功能影响的双盲交叉比较。
Int Clin Psychopharmacol. 2005 Nov;20(6):319-26. doi: 10.1097/00004850-200511000-00007.
Zotero 插件